As global markets navigate the implications of the incoming Trump administration, investors are closely watching sectors influenced by potential policy shifts. In this context, penny stocks—typically smaller or newer companies—remain a compelling area for exploration due to their potential for growth at lower price points. Despite being an outdated term, these stocks can offer significant opportunities when backed by strong financials and solid fundamentals, making them worthy of attention in today's market landscape.
Top 10 Penny Stocks
| Name | Share Price | Market Cap | Financial Health Rating |
| BP Plastics Holding Bhd (KLSE:BPPLAS) | MYR1.21 | MYR340.59M | ★★★★★★ |
| DXN Holdings Bhd (KLSE:DXN) | MYR0.48 | MYR2.39B | ★★★★★★ |
| Rexit Berhad (KLSE:REXIT) | MYR0.77 | MYR133.38M | ★★★★★★ |
| Kelington Group Berhad (KLSE:KGB) | MYR3.40 | MYR2.35B | ★★★★★☆ |
| Seafco (SET:SEAFCO) | THB1.99 | THB1.61B | ★★★★★★ |
| LaserBond (ASX:LBL) | A$0.60 | A$70.33M | ★★★★★★ |
| Hil Industries Berhad (KLSE:HIL) | MYR0.875 | MYR290.45M | ★★★★★★ |
| Lever Style (SEHK:1346) | HK$0.87 | HK$539.57M | ★★★★★★ |
| Next 15 Group (AIM:NFG) | £3.76 | £365M | ★★★★☆☆ |
| Embark Early Education (ASX:EVO) | A$0.81 | A$148.62M | ★★★★☆☆ |
Click here to see the full list of 5,806 stocks from our Penny Stocks screener.
Let's uncover some gems from our specialized screener.
Nykode Therapeutics (OB:NYKD)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies, with a market cap of NOK773.26 million.
Operations: The company generates revenue from its Pharmaceuticals segment, amounting to $6.52 million.
Market Cap: NOK773.26M
Nykode Therapeutics, with a market cap of NOK773.26 million, is navigating a challenging landscape as it remains unprofitable and experiences declining revenues. Recent strategic shifts include regaining control over its VB10.NEO cancer vaccine following the termination of its collaboration with Genentech, which may offer new opportunities for licensing and development. Despite revenue forecasts indicating growth, earnings are expected to decline by 21.2% annually over three years. However, promising data from their inverse vaccine platform targeting autoimmune diseases highlights potential therapeutic breakthroughs in multiple sclerosis treatment, offering hope amidst financial challenges and high volatility in share price.
- Get an in-depth perspective on Nykode Therapeutics' performance by reading our balance sheet health report here.
- Explore Nykode Therapeutics' analyst forecasts in our growth report.
Scana (OB:SCANA)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Scana ASA operates in the offshore, energy, and maritime sectors across various global regions, with a market capitalization of NOK1.30 billion.
Operations: The company generates revenue from its Energy segment with NOK833 million and its Offshore Segment with NOK863.7 million.
Market Cap: NOK1.3B
Scana ASA, with a market cap of NOK1.30 billion, has shown robust financial performance in recent quarters, reporting NOK412.3 million in sales for Q3 2024 and a net income increase to NOK16.9 million. The company’s earnings growth of 101.3% over the past year outpaces its industry peers and reflects high-quality earnings despite some shareholder dilution (2.6%). Scana's debt management is commendable with a significant reduction in its debt-to-equity ratio over five years and interest payments well-covered by EBIT (4.8x). However, it faces volatility challenges and potential acquisition by MIG Finance Namibia for NOK1.8 billion remains pending shareholder approval.
- Navigate through the intricacies of Scana with our comprehensive balance sheet health report here.
- Gain insights into Scana's outlook and expected performance with our report on the company's earnings estimates.
Beyond Securities (SET:BYD)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Beyond Securities Public Company Limited offers securities brokerage services to individual and institutional investors in Thailand, with a market capitalization of approximately THB4.69 billion.
Operations: The company's revenue is primarily derived from its Investment Business, contributing THB582.63 million, and its Securities and Derivatives Business, which adds THB225.49 million.
Market Cap: THB4.69B
Beyond Securities Public Company Limited, with a market cap of THB4.69 billion, has shown financial improvement, reporting THB231.84 million in Q2 2024 revenue compared to negative revenue the previous year. The company turned profitable with a net income of THB30.77 million despite past one-off losses impacting results. Its seasoned management and board contribute to stability, although recent shareholder dilution and high share price volatility pose challenges. Beyond Securities' reduced debt levels and cash surplus over total debt are positive indicators; however, negative operating cash flow suggests potential liquidity concerns that investors should monitor closely.
- Click here to discover the nuances of Beyond Securities with our detailed analytical financial health report.
- Evaluate Beyond Securities' historical performance by accessing our past performance report.
Next Steps
- Click through to start exploring the rest of the 5,803 Penny Stocks now.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Jump on the AI train with fast growing tech companies forging a new era of innovation.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About OB:SCANA
Scana
Engages in the offshore, energy, and maritime businesses in Norway, rest of European countries, America, Asia, Africa, and Oceania.
Flawless balance sheet and undervalued.
